Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
| ▸ | TPH1 | P17752 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044964 | 0.98 | ITGB3 (0.37) | ITGB3ITGA2BSLC7A5PTPN1DPP4 | |
| SCHEMBL3100802 | 0.85 | ITGB3 (0.38) | ITGB3ITGA2BSLC7A5PTPN1DPP4 | |
| SCHEMBL5576438 | 0.81 | SLC7A5 (0.41) | ITGB3ITGA2BSLC7A5PTPN1DPP4 | |
| SCHEMBL4542258 | 0.81 | PTPN1 (0.45) | ITGB3ITGA2BSLC7A5PTPN1DPP4 | |
| Asparagine SCHEMBL10380760 | 0.81 | REN (0.34) | ITGB3ITGA2BSLC7A5PTPN1DPP4 | |
| SCHEMBL1675509 | 0.80 | SLC7A5 (0.44) | ITGB3ITGA2BSLC7A5PTPN1DPP4 | |
| Proline SCHEMBL17728310 | 0.80 | PTPN1 (0.43) | ITGB3ITGA2BSLC7A5PTPN1DPP4 | |
| Asparagine SCHEMBL10379803 | 0.79 | REN (0.33) | ITGB3ITGA2BREN | |
| Threonine SCHEMBL17728293 | 0.79 | SLC7A5 (0.37) | ITGB3ITGA2BSLC7A5PTPN1DPP4 | |
| Tyrosine SCHEMBL4612310 | 0.79 | SLC7A5 (0.48) | SLC7A5DPP4PTGS1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054677-B1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1064010-B1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-02-20 | — | — | EP | claimed |
| EP-1064010-A4 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | CONNECTIVE TISSUE IMAGINEERING (US) | 2004-10-06 | — | — | EP | claimed |
| US-6777389-B1 | INHIBITING CUTANEOUS EFFECTS OF AGING | CONNECTIVE TISSUE IMAGINEERING LLC | 2004-08-17 | — | — | US | claimed |
| CN-1300220-A | Peptide compositions and formulations and use of same | MRS LTD (US) | 2001-06-20 | — | — | CN | claimed |
| EP-1064010-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | Mrs, Llc (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045941-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | MRS, LLC (US) | 1999-09-16 | — | — | WO | claimed |
| EP-1054677-B1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1064010-B1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1392346-A4 | COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE | CONNECTIVE TISSUE IMAGINEERING (US) | 2006-10-25 | — | — | EP | disclosed |
| US-6962904-B1 | Elastin peptide analogs and uses thereof | CONNECTIVE TISSUE IMAGINEERING (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1054677-A4 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | MRS LLC (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050054578-A1 | Elastin peptide analogs and uses thereof | SANDBERG LAWRENCE B (US) | 2005-03-10 | — | — | US | disclosed |
| US-6506731-B1 | Peptide or peptide-like compound(s) of the present invention appear to aid the elasticity and/or turgor of the skin | CONNECTIVE TISSUE IMAGINEERING LLC | 2003-01-14 | — | — | US | disclosed |
| WO-2001091700-A2 | COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE | CONNECTIVE TISSUE IMAGINEERING LLC (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2000028996-A9 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | MRS LLC (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-1064010-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | Mrs, Llc (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1054677-A1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | Mrs, Llc (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000028996-A1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | MRS, LLC (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-1999045941-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | MRS, LLC (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054578-A1 | Elastin peptide analogs and uses thereof | ELANE, CUTA, ENPEP | ITGB3 3496/4885ITGA2B 3971/4885SLC7A5 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.